Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer
Authors:
- Ashish AdlakhaAAAshish Adlakha
- Peter R. BergethonPBPeter R. Bergethon
- 1 October 2006
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (10) , 1475-1478
Abstract
Case Report from JAMA Neurology — Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon CancerKeywords
This publication has 15 references indexed in Scilit:
- Reversible Posterior Leukoencephalopathy Syndrome and BevacizumabNew England Journal of Medicine, 2006
- Circulating Angiogenic Factors in PreeclampsiaClinical Obstetrics and Gynecology, 2005
- Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignanciesAmerican Journal of Hematology, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces ProteinuriaJournal of Biological Chemistry, 2003
- Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-SrcJournal of Biological Chemistry, 1999
- Posterior leukoencephalopathy without severe hypertensionNeurology, 1998
- Multifocal inflammatory leukoencephalopathy with 5‐fluorouracil and levamisoleAnnals of Neurology, 1992
- Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological studyBrain Research, 1976